^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Lymphocytic Leukemia
    Drug:Besponsa (inotuzumab ozogamicin) (DNA replication inhibitor, CD22-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    If patients experience less than a CR...treatment options include chemotherapy, blinatumomab, tisagenlecleucel, or inotuzumab ozogamicin...
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    N Engl J Med
    Title:

    Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

    Excerpt:
    The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease...Both progression-free and overall survival were longer with inotuzumab ozogamicin. 
    DOI:
    10.1056/NEJMoa1509277
    Trial ID:
    INO-VATE
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Leuk Res
    Title:

    Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial

    Excerpt:
    ...patients with relapsed/refractory acute lymphocytic leukemia who received inotuzumab....significantly improved overall survival and progression-free survival, respectively: hazard ratio (97.5% confidence interval; one-sided P-value) 0.512 (97.5% CI [0.313-0.835]; P = 0.0009) and 0.423 (97.5% CI [0.256-0.699]; P < 0.0001)...Median overall survival was 14.1 versus 7.2 months...
    DOI:
    10.1016/j.leukres.2019.106283
    Trial ID:
    INO-VATE